POAI Overview

Kymera Therapeutics Inc.: The company's shares surged 9.58% to $73.00 in after-hours trading, driven by anticipation of results from the BroADen Phase 1b clinical trial for its oral STAT6 degrader for atopic dermatitis, set to be announced on December 8.

Ocular Therapeutix Inc.: Shares increased by 11.29% to $14.00 after hours, following recent progress in its HELIOS-3 Phase 3 program for AXPAXLI in diabetic retinopathy, despite no new updates on Friday.

Predictive Oncology Inc.: The stock jumped 13.62% to $4.84 after hours, rebounding from a significant decline during the day, as the company regained compliance with Nasdaq's minimum stockholders' equity requirement.

Acumen Pharmaceuticals Inc.: Shares rose 3.23% to $1.92 after hours, following a presentation at the CTAD conference on improved delivery of Alzheimer's treatment antibodies, indicating positive long-term development prospects.

U.S. Stock Market Performance: U.S. stocks opened higher, with the Nasdaq Composite gaining approximately 150 points, while the Dow and S&P 500 also saw increases of 0.19% and 0.42%, respectively. Information technology shares rose by 0.8%, while energy stocks fell by 0.8%.

Pending Home Sales Surge: U.S. pending home sales increased by 4% in August, marking the largest gain in five months, contrasting with a 0.4% decline in the previous month.

Notable Stock Movements: Maison Solutions Inc. shares surged by 257%, while Predictive Oncology Inc. rose by 112% following a reverse stock split. Conversely, KALA Bio, MoonLake Immunotherapeutics, and IO Biotech saw significant declines of 92%, 89%, and 75%, respectively.

Global Market Overview: European shares were mostly higher, with the eurozone's STOXX 600 gaining 0.2%. Asian markets closed mixed, with Japan's Nikkei 225 down 0.69% and Hong Kong's Hang Seng up 1.89%.

Private Placement Transactions: Predictive Oncology announced two private placement transactions to raise approximately $344.4 million, involving the sale of common stock and pre-funded warrants for Aethir tokens.

Use of Proceeds: The funds will support the company's digital asset treasury strategy, including acquiring ATH tokens and covering working capital and corporate expenses, with the PIPEs expected to close around October 2, 2025.

Upcoming Stock Splits: The week of September 29 to October 3 will see several companies implementing stock splits, including Leslie’s, Cemtrex, Lunai Bioworks, Erayak Power Solution Group, Predictive Oncology, and American Rebel Holdings, primarily as a strategy to comply with Nasdaq's minimum bid price requirements.

Types of Stock Splits: Companies are utilizing reverse stock splits to reduce share counts and increase share prices, which helps maintain compliance with exchange listing rules and can enhance investor perception, while traditional stock splits aim to make shares more accessible to retail investors.

Reverse Stock Split Announcement: Predictive Oncology Inc. (POAI) has announced a 1-for-15 reverse stock split of its common stock, effective September 30, 2025, where every 15 shares will be combined into one share.

Compliance with Nasdaq Requirements: The reverse stock split aims to help the company meet the minimum bid price requirement for maintaining its listing on the Nasdaq Capital Market.